- Home
- GAMB vs NYXH Comparison
GAMB vs NYXH Comparison
Compare GAMB & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | NYXH |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | Jersey | Belgium |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 126.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GAMB | NYXH |
|---|---|---|
| Price | $2.46 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $8.36 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 1.2M | 241.9K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | $213.98 |
| Revenue Next Year | $8.79 | $126.25 |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.23 | $1.31 |
| 52 Week High | $12.74 | $8.59 |
Technical Indicators
Market Signals| Indicator | GAMB | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 34.94 | 18.84 |
| Support Level | $2.23 | N/A |
| Resistance Level | $5.54 | $5.02 |
| Average True Range (ATR) | 0.12 | 0.16 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 75.95 | 5.03 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.